| 1992 |
NHE3 (NHE-3) encodes a Na+/H+ exchanger isoform with 832 amino acids, 10–12 membrane-spanning domains, and a long cytoplasmic tail with putative protein kinase phosphorylation motifs; it is expressed specifically in intestine and kidney. |
cDNA cloning, sequencing, Northern blot, ribonuclease protection assay |
The Journal of biological chemistry |
High |
1374392
|
| 1993 |
NHE3 protein localizes to the brush-border (apical) membrane of renal proximal tubule cells, identified as an ~80 kDa polypeptide by isoform-specific antibody on Western blot and immunocytochemistry. |
Isoform-specific antibody (Western blot, immunocytochemistry), NHE3-transfected cell controls |
The American journal of physiology |
High |
8238556
|
| 1993 |
NHE3 functions as an electroneutral Na+/H+ exchanger with low amiloride sensitivity, apparent KNa of ~4.7 mM for extracellular Na+, and positive cooperative activation by intracellular H+ (half-maximal pK ~6.45); K+o does not inhibit NHE3 (unlike NHE1). |
Stable transfection in NHE-deficient CHO (AP-1) cells, amiloride-inhibitable 22Na+ influx assay, kinetic analysis |
The Journal of biological chemistry |
High |
8393860
|
| 1995 |
NHE3 is localized to the apical membrane of S1 and S2 proximal convoluted tubules and medullary/cortical thick ascending limbs in rat kidney; cross-linking studies indicate oligomeric forms of the transporter exist. |
Polyclonal antisera against cytoplasmic epitopes, Western blot of fractionated membranes, immunohistochemistry, chemical cross-linking |
Kidney international |
High |
8569082
|
| 1995 |
PKA activation acutely inhibits NHE3 activity (~39% inhibition); this requires the cytoplasmic C-terminal domain of NHE3, and the purified recombinant cytoplasmic domain is phosphorylated by PKA catalytic subunit in vitro on serine residues; cAMP increases NHE3 phosphocontent ~3-fold in cells. |
Stable expression in AP-1 fibroblasts, Xenopus oocyte expression with truncation mutants, in vitro PKA phosphorylation of recombinant domain, immunoprecipitation of phospho-NHE3 |
The Journal of clinical investigation |
High |
7593604
|
| 1995 |
NHE-1, NHE-2, and NHE-3 are electroneutral and voltage-independent Na+/H+ exchangers; currents observed in some cell types during exchange are due to a pre-existing H+ conductance, not the exchanger itself. |
Whole-cell patch clamp combined with microfluorimetric pH measurement, CHO cells transfected with NHE isoforms, Zn2+ dissociation experiment |
The Journal of general physiology |
High |
7494140
|
| 1998 |
NHE3 knockout mice (Slc9a3-/-) exhibit reduced HCO3- and fluid absorption in proximal convoluted tubules, a severe intestinal absorptive defect, mild acidosis, reduced blood pressure, and compensatory upregulation of AE1, renin, colonic H+,K+-ATPase, and ENaC; NHE3 is the major absorptive Na+/H+ exchanger in kidney and intestine. |
Gene targeting/knockout mouse model, blood chemistry, renal tubule perfusion, intestinal flux measurements |
Nature genetics |
High |
9662405
|
| 1998 |
E3KARP (NHERF2) directly binds NHE3 at an internal region in its C-terminal cytoplasmic tail via E3KARP's second PDZ domain plus C-terminal domain; E3KARP also binds the cytoskeletal protein ezrin, suggesting a scaffold linking NHE3 to ezrin and thereby to PKA (type II). |
In vitro binding assays (pulldown), co-localization in PS120 fibroblasts, deletion/domain mapping |
The Journal of biological chemistry |
High |
9748260
|
| 1998 |
PI3-kinase activity is required for recycling of intracellular NHE3 to the cell surface; PI3-K inhibitors (wortmannin, LY294002) reduce NHE3 plasma membrane expression by decreasing the rate of recycling of endosomal NHE3, thereby inhibiting NHE3-mediated H+ extrusion. |
PI3-K inhibitors, epitope-tagged NHE3 in AP-1 cells, immunofluorescence microscopy, ELISA-based surface quantification, temperature-block experiments |
The Journal of biological chemistry |
High |
9694828
|
| 1999 |
cAMP inhibition of NHE3 requires PKA (dominant-negative PKA-regulatory subunit abolishes the effect) and involves in vivo phosphorylation of NHE3 at Ser-552 and Ser-605; single or multiple mutations at these serines reduce PKA regulation, though complex mechanisms involving additional serines also contribute. |
Dominant-negative PKA expression, site-directed mutagenesis (8 serines mutated), in vitro PKA phosphorylation, tryptic phosphopeptide mapping of in vivo phosphorylated NHE3 |
The Journal of biological chemistry |
High |
9933588
|
| 1999 |
NHERF and E3KARP are necessary for cAMP-dependent phosphorylation of NHE3 in vivo; they act as adapters facilitating PKA-mediated phosphorylation of NHE3, but phosphorylation of NHERF itself is not required for this effect. |
Co-immunoprecipitation, in vivo phosphorylation assay, dominant-negative NHERF mutant (triple Ser→Ala), 8-Br-cAMP treatment in PS120 fibroblasts |
The Journal of biological chemistry |
High |
10455146
|
| 1999 |
PTH acutely inhibits NHE3 in a biphasic manner: early inhibition (5 min) via NHE3 phosphorylation on multiple serines, followed by dynamin-dependent endocytosis that decreases surface NHE3 antigen (detectable at 30 min); blocking endocytic trafficking with dominant-negative dynamin (K44A) abolishes the late but not early inhibition. |
Dominant-negative dynamin mutant, surface NHE3 quantification, phosphorylation assay, OKP cell model |
The Journal of biological chemistry |
High |
10866993
|
| 1999 |
In vivo PTH infusion provokes redistribution of ~25% of NHE3 from apical membranes to intracellular membrane fractions in renal proximal tubule, associated with natriuresis/diuresis; cAMP-PKA signaling is necessary for NHE3 and NaPi2 internalization. |
Intravenous PTH infusion in rats, sorbitol density gradient fractionation of renal cortex membranes, immunoblotting |
The American journal of physiology |
High |
10330053
|
| 1999 |
ETB receptor activation increases NHE3 phosphorylation on multiple threonine and serine residues in OKP cells, with ETB but not ETA receptor specificity; phosphorylation correlates temporally with activation of NHE3 activity. |
Stable transfection of ETB vs ETA receptor cDNA in OKP cells, immunoprecipitation, phosphoamino acid analysis, SDS-PAGE mobility shift, alkaline phosphatase treatment |
The American journal of physiology |
High |
10199826
|
| 2000 |
G protein subunit Gsα directly associates with and regulates NHE3 in renal brush-border membrane vesicles independently of cytoplasmic second messengers; D1-like receptor-mediated inhibition of NHE3 is partially reversed by anti-Gsα antibodies, and GTPγS increases Gsα co-immunoprecipitation with NHE3; Gβγ dimers appear to have a stimulatory effect on NHE3. |
Brush-border membrane vesicles devoid of cytoplasmic components, anti-G protein antibodies, co-immunoprecipitation, D1 agonist fenoldopam |
American journal of physiology. Regulatory, integrative and comparative physiology |
Medium |
10749796
|
| 2001 |
NHERF co-localizes with NHE3 and ezrin specifically in the apical membrane of proximal tubule cells in rat kidney; NHERF2 is absent from proximal tubule but present in collecting duct where it co-localizes with ROMK, indicating isoform-specific compartmentalization. |
Isoform-specific antibodies, immunocytochemical analysis of rat kidney sections |
American journal of physiology. Cell physiology |
Medium |
11121391
|
| 2001 |
Dopamine (DA) acutely decreases surface NHE3 via stimulation of NHE3 endocytosis through clathrin-coated vesicles; this requires GTPase dynamin, involves increased NHE3 binding to adaptor protein AP2, and is dependent on PKA-mediated phosphorylation of NHE3 at Ser-560 and Ser-613. |
Surface NHE3 antigen quantification, dominant-negative dynamin, AP2 binding assay, PKA inhibition (pharmacological and genetic), Ser→Ala mutations, renal cell line |
The Journal of biological chemistry |
High |
11328806
|
| 2001 |
Ileal brush-border NHE3 exists in three pools: ~50% Triton X-100 soluble, ~50% detergent-insoluble, of which ~33% resides in cholesterol-enriched lipid rafts. EGF and clonidine increase the raft pool of NHE3 in the brush border, associated with increased NHE3 activity; lipid rafts and actin cytoskeleton regulate NHE3 basal endocytosis. |
Detergent extraction, density gradient fractionation (OptiPrep), EEA1-immunoisolated early endosomes, cholesterol depletion with MβCD, cytochalasin D |
The Journal of physiology |
High |
11731584
|
| 2001 |
NHE3 is activated downstream of SGLT1-mediated Na+-glucose cotransport in intestinal epithelial cells, causing NHE3-dependent cytoplasmic alkalinization that requires p38 MAP kinase activity; p38 MAP kinase activation also occurs with Na+-glucose cotransport and is sufficient to trigger NHE3-dependent alkalinization when activated alone. |
pH-sensitive dye (BCECF), NHE3-preferential inhibitor S-3226, p38 MAP kinase inhibitors (PD-169316, SB-202190), anisomycin activation, Caco-2 cell monolayers |
American journal of physiology. Cell physiology |
High |
11600416
|
| 2002 |
Ca2+-dependent inhibition of NHE3 requires E3KARP (not NHERF), and depends on Ca2+-dependent association of α-actinin-4 with E3KARP (via α-actinin-4's actin-binding plus spectrin repeat domain), forming an NHE3–E3KARP–α-actinin-4 complex; elevated Ca2+ causes NHE3 oligomerization and endocytosis, inhibiting activity. |
PS120 fibroblasts stably expressing E3KARP or NHERF, co-immunoprecipitation, dominant-negative α-actinin-4 fragment, ionomycin treatment, NHE3 activity assay |
The Journal of biological chemistry |
High |
11948184
|
| 2002 |
NHE3 supports receptor-mediated, clathrin-dependent endocytosis (RME) in proximal tubule cells by maintaining endosomal pH homeostasis and endocytic fusion; NHE3 confers cAMP sensitivity to RME, and NHE3 deficiency abolishes cAMP effects on endosomal pH and RME. |
Cellular knockout/retransfection in OKP cells, albumin uptake assay, endosomal pH measurement, cAMP treatment |
American journal of physiology. Renal physiology |
High |
12167607
|
| 2004 |
Ezrin phosphorylation at Thr567 is required for NHE3 recruitment to the apical membrane after Na+-glucose cotransport; this occurs downstream of p38 MAP kinase, and a dominant-negative N-terminal ezrin construct blocks NHE3 membrane recruitment and cytoplasmic alkalinization without affecting p38 activation. |
Dominant-negative ezrin construct, phospho-specific antibody for Thr567, p38 MAP kinase inhibitors, cell surface NHE3 quantification, intestinal epithelial cells |
Proceedings of the National Academy of Sciences of the United States of America |
High |
15197272
|
| 2004 |
Akt2 phosphorylates ezrin at Thr567 in vitro and in cells downstream of PI3-kinase and p38 MAP kinase; Akt2-specific siRNA knockdown prevents ezrin phosphorylation, NHE3 translocation, and NHE3 activation after Na+-glucose cotransport. |
In vitro Akt kinase assay with recombinant ezrin, Akt2-specific siRNA, PI3-K inhibitors, Akt inhibitors, NHE3 surface translocation assay |
The Journal of biological chemistry |
High |
15531580
|
| 2004 |
Carbachol inhibits ileal NHE3 activity by stimulating NHE3 endocytosis from the brush border (detergent-soluble fraction) into early endosomes; carbachol increases the size of NHE3-containing complexes (specifically in detergent-resistant fraction), enhancing co-immunoprecipitation of NHERF2, α-actinin-4, and PKC with NHE3; this inhibition is fully abolished by Src family kinase inhibitor PP2. |
OptiPrep gradient centrifugation, sucrose gradient centrifugation for complex size, co-immunoprecipitation, surface biotinylation, PP2 Src inhibitor, ileal preparations |
The Journal of physiology |
High |
14978207
|
| 2005 |
Glucocorticoid (dexamethasone) activation of NHE3 requires SGK1-mediated phosphorylation of NHE3 at Ser663; in vitro SGK1 kinase assay confirms phosphorylation at Ser663; S663A mutation blocks dexamethasone effect; phosphorylation precedes increased NHE3 activity and is associated with increased surface NHE3 expression. |
In vitro SGK1 kinase assay, site-directed mutagenesis (S663A), surface biotinylation, pH-sensitive dye NHE3 activity assay |
American journal of physiology. Cell physiology |
High |
15888551
|
| 2005 |
NHERF2 (but not NHERF1) acts as a cGMP-dependent protein kinase G (cGKII) anchoring protein; cGKII must be membrane-anchored via its myristoyl group and bound to NHERF2 to inhibit NHE3; NHERF2 PDZ2 C-terminus binds both NHE3 and cGKII, enabling cGMP inhibition of NHE3. |
PS120 cell co-expression system, in vitro NHERF-cGKII binding assay, non-myristoylated cGKII mutant, NHE3 activity assay, cAMP/cGMP analog pharmacology |
The Journal of biological chemistry |
High |
15722341
|
| 2005 |
Glucocorticoids acutely increase surface NHE3 via stimulation of NHE3 exocytosis (insertion), without changes in total NHE3 protein or NHE3 endocytosis; this effect does not require new protein synthesis. |
Surface biotinylation, biotinylatable NHE3 insertion assay (sulfo-NHS-acetate blockade), MesNa cleavage endocytosis assay, cycloheximide treatment in OKP cells |
American journal of physiology. Renal physiology |
High |
15942046
|
| 2006 |
EPAC (exchange protein directly activated by cAMP) provides a second, PKA-independent pathway for cAMP inhibition of NHE3 activity; EPAC activation inhibits NHE3 without inducing phosphorylation of NHE3 at serines 552/605 and without redistribution of NHE3 from brush-border membrane. |
cAMP analogs selective for PKA vs. EPAC, PKA activity assay, H89 inhibitor, NHE3 phosphorylation assay, surface NHE3 quantification in OK cells and murine kidney slices |
Proceedings of the National Academy of Sciences of the United States of America |
High |
16407144
|
| 2006 |
TNF causes NHE3 internalization from the intestinal brush border via PKCα activation, leading to Na+ malabsorption; PKCα inhibition (pharmacological or genetic) prevents NHE3 internalization and diarrhea despite continued barrier dysfunction, demonstrating that coordinated NHE3 inhibition and barrier dysfunction are both required for TNF-mediated diarrhea. |
In vivo T cell activation mouse model, surface NHE3 quantification, pharmacological and genetic PKCα inhibition, Na+ absorption measurement |
The Journal of clinical investigation |
High |
17016558
|
| 2006 |
Aldosterone inhibits apical NHE3 and HCO3- absorption in the medullary thick ascending limb (MTAL) through a rapid, nongenomic ERK-dependent pathway; aldosterone activates ERK within 5 min, and MEK/ERK inhibitors (U-0126, PD-98059) prevent both ERK activation and NHE3 inhibition; spironolactone and actinomycin D do not block this effect. |
In vitro perfused rat MTALs, HCO3- flux measurement, ERK immune-complex kinase assay, MEK/ERK inhibitors, spironolactone, actinomycin D |
American journal of physiology. Renal physiology |
High |
16757729
|
| 2007 |
NHE3 phosphorylation at Ser552 and Ser605 by PKA is dissociated from changes in NHE3 transport activity; dramatic phosphorylation at these sites occurs without altered NHE3 activity in vivo (PTH-infused rats) and precedes transport inhibition in vitro, indicating these phosphorylations do not directly inhibit NHE3. |
PTH infusion in Sprague-Dawley rats, phosphospecific monoclonal antibodies to pSer552 and pSer605, microvillar membrane vesicle NHE3 activity assay, 22Na uptake in OKP cells |
American journal of physiology. Renal physiology |
High |
17409282
|
| 2007 |
Synaptotagmin I (Syt I) binds NHE3, co-immunoprecipitates with NHE3 preferentially after cAMP or Ca2+ elevation, and is required for cAMP- and Ca2+-induced NHE3 endocytosis; Syt I siRNA blocks NHE3 endocytosis without preventing NHE3 activity inhibition; Syt I interaction with NHE3 precedes and is required for recruitment of AP2 and clathrin. |
Co-immunoprecipitation, siRNA of Syt I/AP2/clathrin, 22Na influx, apical membrane biotin labeling, confocal microscopy in Caco-2BBe cells and mouse jejunum |
American journal of physiology. Gastrointestinal and liver physiology |
High |
17307723
|
| 2008 |
NHE3's C-terminal domain directly binds ezrin via a positively charged juxtamembrane cluster (K516, R520, R527) interacting with the FERM domain III of ezrin; this direct NHE3–ezrin binding is necessary for basal exocytosis, delivery from synthetic pathway, and brush border movement of NHE3. |
In vitro binding assays with domain deletions and point mutants, biochemical fractionation, surface NHE3 quantification |
Clinical and experimental pharmacology & physiology |
Medium |
18430067
|
| 2008 |
IRBIT (IP3 receptor-binding protein released with IP3) binds the C-terminal domain of NHE3 and mediates Ca2+-dependent activation of NHE3 via exocytic trafficking to the plasma membrane; this activation requires calmodulin and CaM-dependent kinase II, and IRBIT can reverse NHERF2-dependent Ca2+-inhibition of NHE3. |
Co-immunoprecipitation, siRNA knockdown of IRBIT, exocytosis assay, calmodulin inhibitor, CaM kinase II inhibitor, NHE3 activity assay |
The Journal of biological chemistry |
High |
18829453
|
| 2008 |
Casein kinase 2 (CK2) binds to the NHE3 C-terminal domain (aa 590–667) and phosphorylates a separate site, Ser719, to stimulate basal NHE3 activity; S719A mutation reduces NHE3 surface expression by decreasing exocytosis and plasma membrane delivery; CK2 inhibitor DMAT inhibits NHE3 carrying S719 but not S719A mutant. |
LC-MS/MS identification of phosphorylation site, in vitro CK2 kinase assay, S719A/S719D mutagenesis, surface biotinylation, exocytosis assay, CK2 inhibitor DMAT, co-immunoprecipitation |
Molecular biology of the cell |
High |
18614797
|
| 2011 |
SGK3, localized to recycling endosomes (via its Arg90-dependent PX domain), acutely activates NHE3 within 15 min of glucocorticoid treatment in a PI3K- and PDK1-dependent manner; PDK1 translocates to endosomes upon dexamethasone treatment; mutation of SGK3 Arg90 disrupts endosomal localization and delays NHE3 activation. |
Transfection of SGK isoforms in PS120 and Caco-2bbe cells, immunofluorescence colocalization, R90A point mutation, PI3K and PDK1 inhibitors, NHE3 activity assay, SGK1/NHERF2 knockout mouse comparison |
Molecular biology of the cell |
High |
21865597
|
| 2014 |
cGKII inhibits NHE3 by phosphorylating it at three required sites (rabbit Ser554, Ser607, Ser663; mouse Ser552, Ser605, Ser659); all three phosphorylations must be present simultaneously for cGMP inhibition; cGMP/cGKII reduces surface NHE3. Additionally, Ser663 phosphorylation by dexamethasone is required for glucocorticoid stimulation of NHE3 activity and surface expression. |
iTRAQ/LC-MS/MS with TiO2 enrichment, phosphospecific antibodies, site-directed mutagenesis, surface biotinylation, NHE3 activity assay in PS120/NHERF2, Caco-2bbe, and mouse ileum |
The Journal of biological chemistry |
High |
25480791
|
| 2015 |
Loss-of-function SLC9A3 missense mutations (in the N-terminal transport domain and membrane-spanning regions) cause congenital sodium diarrhea; functionally, these mutations reduce NHE3 activity by decreasing basal surface expression and/or abolishing basal transport function of NHE3 in plasma membrane NHE null fibroblasts, while acute regulation remains normal. |
Whole-exome sequencing, Sanger sequencing, functional expression of mutants in NHE null fibroblasts, Na+/H+ exchange activity assay, surface expression assay |
Human molecular genetics |
High |
26358773
|
| 2015 |
NHE3 and scaffold proteins NHERF1, IRBIT, and ezrin form macrocomplexes in the intestinal brush border; in streptozotocin-diabetic mice these macrocomplexes are disrupted, reducing NHE3 activity; insulin restores the macrocomplexes and NHE3 surface expression. IRBIT facilitates NHE3–NHERF1 interaction via protein kinase D2-dependent phosphorylation, and insulin-stimulated ezrin phosphorylation enhances ezrin–NHERF1–IRBIT–NHE3 interactions. |
Co-immunoprecipitation, diabetic mouse model, insulin treatment, NHERF1/IRBIT siRNA knockdown, NHE3 trafficking assay, PKD2 knockdown |
The Journal of clinical investigation |
High |
26258413
|
| 2020 |
Tubule-specific NHE3 knockout mice do not respond to empagliflozin (SGLT2 inhibitor) with increased urinary Na+ and bicarbonate excretion or urine pH change, demonstrating that renal NHE3 is required for the natriuretic effect of empagliflozin; empagliflozin in diabetic mice increases NHE3 phosphorylation at S552/S605 (linked to reduced NHE3-mediated reabsorption). |
Tubule-specific NHE3 knockout mouse (Pax8-Cre), acute empagliflozin dosing, urine electrolyte/pH measurement, phosphospecific NHE3 antibodies |
American journal of physiology. Renal physiology |
High |
32893663
|
| 2020 |
Inducible intestinal epithelial cell-specific NHE3 knockout mice develop watery alkaline diarrhea, metabolic acidosis, hyponatremia, hyperkalemia, and elevated aldosterone, demonstrating that intestinal NHE3 is essential for Na+, acid-base, and volume homeostasis. |
Tamoxifen-inducible intestinal epithelial NHE3 knockout (Villin-CreERT2), blood chemistry, urinary and fecal measurements |
Clinical science (London, England : 1979) |
High |
32227118
|
| 1996 |
ETB receptor (but not ETA) activation increases Na+/H+ antiporter (NHE3) activity in OKP cells via Ca2+/calmodulin kinase pathway (~50%) and tyrosine kinase pathway (~50%); Ca2+ elevation alone (through ETA) is not sufficient for activation. |
Stable ETB and ETA receptor transfection in OKP cells, BAPTA Ca2+ clamping, KN62 (CaM kinase inhibitor), pertussis toxin, PKC/PLA2/COX inhibitors |
The Journal of clinical investigation |
High |
8617878
|
| 1996 |
ETB receptor-induced NHE3 activation is 50% mediated by tyrosine kinase pathways, involving p210 (integral membrane protein); ET-1 causes tyrosine phosphorylation of focal adhesion proteins (paxillin, p125FAK) via ETB, but these are not required for Na+/H+ antiporter activation. |
Cytochalasin D disruption of focal adhesions, immunoprecipitation identifying paxillin and p125FAK, tyrosine phosphorylation assay |
The American journal of physiology |
Medium |
8843705
|
| 2002 |
c-Src and ERK are both required for acid-induced activation of NHE3 in renal proximal tubule cells; dominant-negative c-Src (K295M) prevents NHE3 activation and acidosis activates both c-Src and ERK/MEK (but not JNK) independently; MEK inhibition (PD98059) also blocks NHE3 activation by acid. |
Dominant-negative c-Src transfection, immune complex kinase assays (enolase, MBP, GST-c-Jun substrates), MEK inhibitor PD98059, in vivo renal cortical kinase activation |
Kidney international |
High |
12081562
|
| 2007 |
PDZK1 (NHERF3) is required for cAMP- and Ca2+-mediated inhibition of NHE3 in native colonic enterocytes but not for NHE3 abundance, apical targeting, or hyperosmolarity-induced inhibition; pdzk1-/- mice show drastically reduced acid-activated NHE3 activity and abolished responses to forskolin and ionomycin. |
pdzk1 knockout mice, fluorometric NHE3 activity assay in isolated colonic crypts, Western blot, immunohistochemistry, selective NHE3 inhibitor S1611 |
The Journal of physiology |
High |
17395628
|
| 2017 |
Loss of SLC9A3 in mice dramatically decreases CFTR protein expression in the epididymis and vas deferens, leading to obstructive azoospermia with abnormal secretions, calcification, and disorganized stereocilia in the male reproductive tract. |
Slc9a3 knockout mice, immunoblotting of CFTR, immunohistochemistry, ultrastructural analysis (electron microscopy) |
PLoS genetics |
High |
28384194
|